Summary
ABSTRACT Rapid and sensitive point of care tests that can detect all forms of drug resistance in tuberculosis (TB) are urgently needed to address the rise of drug resistance. We propose to develop a novel mutation detection system that uses recently developed nanoreactor bead chemistry and the Blink Diagnostic’s testing platform to identify both the presence of Mycobacterium tuberculosis (Mtb) and all of the clinically important mutations associated with isoniazid (INH), rifampin (RIF), ethambutol (EMB), pyrazinamide (PZA), fluoroquinolone (FQ), linezolid (L), bedaquiline (B), and pretomanid/
